Jan 14, 2021 / 09:30PM GMT
Katja Lange - JPMorgan Chase & Co. - Executive Director in healthcare coverage team
Good afternoon, everyone, and thank you for joining us. My name is Kat Lange, and I'm a member of the health care investment banking team at JPMorgan; it's our great pleasure to have Neoleukin with us today. (Operator Instructions)
And with that, I'd like to hand it over to Jonathan Drachman, CEO of Neoleukin.
Jonathan G. Drachman - Neoleukin Therapeutics, Inc. - CEO, President & Director
Thank you very much, Kat, and thank you to JPMorgan for the invitation to tell you about Neoleukin Therapeutics today and about some of the things that we're really looking forward to in 2021.
On Slide 2 is our forward-looking statement. For additional information on risk factors, I refer you to our periodic filings with the SEC, which can also be found on our website.
Slide 3 gives a brief overview of the history of Neoleukin Therapeutics, which was founded in 2018 based on technology from the University of Washington's Institute for Protein Design that
Neoleukin Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 15, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers